DuPont de Nemours, Inc. (DD) Guidance & Earnings Results

On 2026-08-04 DuPont de Nemours, Inc. raised guidance: "FY26 net sales raised to $7.16-7.19B; operating EBITDA raised to $1.75-1.77B; adjusted EPS raised to $7.17-7.32; organic sales growth expected slightly above…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

DDDuPont de Nemours, Inc.Follow DD — free

Specialty Chemicals · Basic Materials

—

Price chart with a free account

Market cap: 18.4B
P/E TTM: —
Dividend yield: 1.8%
52-week: —
Next earnings: 3 Nov, in 10 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
4 Aug 26	Raised	FY26 net sales raised to $7.16-7.19B; operating EBITDA raised to $1.75-1.77B; adjusted EPS raised to $7.17-7.32; organic sales growth expected slightly above 4% · full year
5 May 26	Raised	FY26 net sales $7,155-$7,215M, operating EBITDA $1,730-$1,760M, adjusted EPS $2.35-$2.40 · full year
10 Feb 26	Raised	Initiated Q1 and FY2026 guidance; exceeded Q4 and FY2025 guidance · full year
6 Nov 25	Raised	FY 2025 operating EBITDA guidance raised to $1.6B · full year
5 Aug 25	Raised	FY2025: Net sales ~$12.85B (from prior ~$12.7B implied), Operating EBITDA ~$3.36B (from prior ~$3.3B implied), Adjusted EPS ~$4.40 (from prior ~$4.25 implied). Q3 2025: Net sales ~$3.32B, Operating EBITDA ~$875M, Adjusted EPS ~$1.15. · full year

DuPont de Nemours, Inc. — questions

What guidance did DuPont de Nemours, Inc. give?: On 2026-08-04: "FY26 net sales raised to $7.16-7.19B; operating EBITDA raised to $1.75-1.77B; adjusted EPS raised to $7.17-7.32; organic sales growth expected slightly above 4%"
When does DuPont de Nemours, Inc. report earnings?: DuPont de Nemours, Inc.'s next earnings report is expected on 2026-11-03.

Every figure on this page comes from DuPont de Nemours, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.